As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

Amgen (Nasdaq: AMGN) has completed construction of a $550 million drug manufacturing facility in the Wake County town.

Amgen Inc . (NASDAQ:AMGN), a leading biopharmaceutical company with a market capitalization of $149 billion, is navigating a ...

Amgen executives and employees, local and state elected dignitaries, and an assortment of other local economic development ...

Amgen Inc. (NASDAQ:AMGN) is a biotechnology powerhouse with an excellent track-record on developing and commercialising products targeting four main therapeutic areas: general medicine ...

When talking about growth in the years to come, Amgen has several levers it can pull. For starters, we can look at already approved products with growth potential. Tepezza, which became part of ...

High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, stocks that pay dividends regularly can be great addition ...

Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel.

Equities research analysts at William Blair reduced their FY2024 earnings per share estimates for shares of Amgen in a ...

Avior Wealth Management LLC trimmed its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 49.8% during the fourth quarter, ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Amgen's established products also face ongoing competitive pressures. The company must continue to innovate and demonstrate the value of its therapies to maintain market share and drive growth.